Fatty Liver: all 1,462 studies

Page 4 of 15. Open to participants first (289), then studies with results posted, then the rest; newest registration first within each.

• Phase 2a Study of HU6 in Subjects With Elevated Liver Fat and High BMI VolunteersCompletedNCT04874233Phase 2Results posted
• Study in Healthy Adults Evaluating PF-07202954CompletedNCT04857437Phase 1Results posted
• Noninvasive Biomarkers of Metabolic Liver Disease 1.1CompletedNCT04828551Not applicableResults posted
• A Study to Test Safety and Efficacy of Survodutide (BI456906) in Adults With Non-alcoholic Steatohepatitis (NASH) and Fibrosis (F1-F3)CompletedNCT04771273Phase 2Results posted
• A Study of Efruxifermin in Non-Cirrhotic Subjects With Histologically Confirmed Nonalcoholic Steatohepatitis (NASH)CompletedNCT04767529Phase 2Results posted
• A Study of the Safety and Tolerability of LPCN 1144 in Subjects Who Completed the LPCN 1144-18-002 TrialCompletedNCT04685993Phase 2Results posted
• A Study to Assess the Safety and Efficacy of Oral Insulin in T2DM Patients With Nonalcoholic Steatohepatitis (NASH)CompletedNCT04618744Phase 2Results posted
• A Study of Oral Insulin to Reduce Liver Fat Content in Type 2 Diabetes Patients With Nonalcoholic Steatohepatitis (NASH)CompletedNCT04616014Phase 2Results posted
• Quantitative Ultrasound With Liver Incytes for Evaluation of Non-Alcoholic Fatty Liver DiseaseTerminatedNCT04576923Not applicableResults posted
• Leronlimab (PRO 140) in Patients With Nonalcoholic SteatohepatitisCompletedNCT04521114Phase 2Results posted
• A Study of CRV431 Dosed Once Daily in NASH Induced F2 and F3 SubjectsCompletedNCT04480710Phase 2Results posted
• Low GI Diet Effects on Non-Alcoholic Fatty Liver DiseaseCompletedNCT04415632Not applicableResults posted
• Study of Pharmacodynamics and Safety of DGAT2i and ACCi Coadministered in Participants With Sponsor-defined Presumed Non Alcoholic SteatohepatitisCompletedNCT04399538Phase 2Results posted
• A Randomized, Double-blind Study to Assess the Safety and Efficacy of EDP-305 in Subjects With Liver-biopsy Proven NASHTerminatedNCT04378010Phase 2Results posted
• Effects of High-Intensity Interval Training Exercise in Adolescents With HepatosteatosisCompletedNCT04342390Not applicableResults posted
• LIFT Study: A Safety, Tolerability, Efficacy, and Pharmacokinetics Study of TERN-101 in Subjects With Non-Cirrhotic Non-Alcoholic Steatohepatitis (NASH)CompletedNCT04328077Phase 2Results posted
• Study of PXL065 in Patients With Nonalcoholic Steatohepatitis (NASH)CompletedNCT04321343Phase 2Results posted
• Metabolic Interventions to Resolve Non-alcoholic Steatohepatitis (NASH) With Fibrosis (MIRNA)CompletedNCT04321031Phase 2Results posted
• Effect of Intermittent Calorie Restriction on MASLD Patients With Abnormal Glucose MetabolismCompletedNCT04283942Not applicableResults posted
• Safety and Effectiveness of BMS-986263 in Adults With Compensated Cirrhosis (Liver Disease) From Nonalcoholic Steatohepatitis (NASH)TerminatedNCT04267393Phase 2Results posted
• Identification of Fatty Liver With Advanced Fibrosis in Type 2 Diabetes Using Simple Fibrosis Scores and Electronic Reminder MessagesCompletedNCT04241575Not applicableResults posted
• A Study of Secukinumab Treatment in Patients With Plaque Psoriasis and Coexisting Non-alcoholic Fatty Liver Disease (NAFLD)TerminatedNCT04237116Phase 3Results posted
• Study of Semaglutide for Non-Alcoholic Fatty Liver Disease (NAFLD), a Metabolic Syndrome With Insulin Resistance, Increased Hepatic Lipids, and Increased Cardiovascular Disease Risk (The SLIM LIVER Study)CompletedNCT04216589Phase 2Results posted
• Study of Aldafermin (NGM282) in Subjects With Compensated Cirrhosis (ALPINE 4)CompletedNCT04210245Phase 2Results posted
• Vitamin E and DHA-EE on NAFLD - Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Clinical Trial (PUVENAFLD)CompletedNCT04198805Phase 2Results posted
• Effect of Probiotics in Non-alcoholic Fatty Liver Disease and SteatohepatitisTerminatedNCT04175392Phase 1/2Results posted
• A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of BFKB8488A Compared With Placebo in Participants With Non-Alcoholic SteatohepatitisTerminatedNCT04171765Phase 2Results posted
• A Study of Tirzepatide (LY3298176) in Participants With Nonalcoholic Steatohepatitis (NASH)CompletedNCT04166773Phase 2Results posted
• Study of Various Treatments in Non-alcoholic Fatty Liver Disease (NAFLD) Patients Who Have Aspects of Non-alcoholic Steatohepatitis (NASH)TerminatedNCT04147195Phase 2Results posted
• The Efficacy, Safety and Tolerability of Oral LPCN 1144 in Subjects With Nonalcoholic SteatohepatitisCompletedNCT04134091Phase 2Results posted
• Study of the Safety and Tolerability of AXA1957 in Adolescent Subjects With Non-Alcoholic Fatty Liver Disease (NAFLD)TerminatedNCT04073407Not applicableResults posted
• Study of the Safety and Tolerability of AXA1125 and AXA1957 in Subjects With Non-Alcoholic Fatty Liver Disease (NAFLD)CompletedNCT04073368Not applicableResults posted
• Efficacy, Safety and Tolerability of the Combination of Tropifexor & Licogliflozin and Each Monotherapy, Compared With Placebo in Adult Patients With NASH and Liver Fibrosis.TerminatedNCT04065841Phase 2Results posted
• A Phase 2b Study of Icosabutate in Fatty Liver DiseaseCompletedNCT04052516Phase 2Results posted
• Study to Evaluate the Efficacy and Safety of CC-90001 in Participants With Non-alcoholic Steatohepatitis (NASH) and Liver FibrosisTerminatedNCT04048876Phase 2Results posted
• A Multiple Ascending Dose Study of Pegozafermin in Participants With Biopsy Confirmed Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) and at High Risk of NASHCompletedNCT04048135Phase 1/2Results posted
• Aspirin for the Treatment of Nonalcoholic Fatty Liver DiseaseCompletedNCT04031729Phase 1/2Results posted
• A Study to Evaluate Safety and Pharmacodynamic Efficacy of 0382 in Obese Subjects With NAFLD/NASH.CompletedNCT04019561Phase 2Results posted
• Safety, Tolerability, and Efficacy of Monotherapy and Combination Regimens in Participants With Nonalcoholic Steatohepatitis (NASH)CompletedNCT03987074Phase 2Results posted
• A Study of Efruxifermin in Subjects With Histologically Confirmed Nonalcoholic Steatohepatitis (NASH)CompletedNCT03976401Phase 2Results posted
• A Double-blind Study to Assess 2 Doses of an Investigational Product for 16 Weeks in Participants With Non-alcoholic Fatty Liver Disease and Type 2 Diabetes MellitusCompletedNCT03969719Phase 2Results posted
• The Sonic Incytes Liver Incyte System, Assessment of Liver Fibrosis and SteatosisCompletedNCT03957070Not applicableResults posted
• Study of TVB-2640 in Subjects With Non-Alcoholic Steatohepatitis (NASH)CompletedNCT03938246Phase 2Results posted
• Elafibranor, PK and Safety in Children and Adolescents 8 to 17 Years of Age With Non Alcoholic Steatohepatitis (NASH)TerminatedNCT03883607Phase 2Results posted
• Saroglitazar Magnesium in the Treatment of Non-Alcoholic SteatohepatitisCompletedNCT03863574Phase 2Results posted
• Structured Mobile Technology Based Lifestyle Program vs Usual Care for Patients With Non-alcoholic Fatty Liver DiseaseCompletedNCT03839082Not applicableResults posted
• Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Participants With Presumed Nonalcoholic Steatohepatitis (NASH)TerminatedNCT03823703Phase 2Results posted
• Safety, Tolerability, Pharmacokinetics and Efficacy of EYP001a in Patients With Nonalcoholic Steatohepatitis (NASH)CompletedNCT03812029Phase 2Results posted
• A Study To Assess Pharmacodynamics, Safety And Tolerability Of PF-05221304 And PF-06865571 Co-Administered For 6 Weeks In Adults With Non-Alcoholic Fatty Liver Disease.CompletedNCT03776175Phase 2Results posted
• A Study of the Efficacy and Safety of PXL770 Versus Placebo After 12 Weeks of Treatment in Patients With NAFLDCompletedNCT03763877Phase 2Results posted
• Oral Amino Acid Nutrition to Improve Glucose Excursions in PCOSCompletedNCT03717935Not applicableResults posted
• Vitamin E for NASH Treatment in HIV Infected IndividualsTerminatedNCT03669133Phase 2Results posted
• An Evaluation of the Safety and Efficacy of Nitazoxanide on Collagen Turnover in NASH Patients With FibrosisCompletedNCT03656068Phase 2Results posted
• Safety, Tolerability, and Efficacy of Saroglitazar Mg 4 mg in Liver Transplant Recipients With Nonalcoholic Fatty Liver Disease (NAFLD)CompletedNCT03639623Phase 2Results posted
• Companion Protocol for ¹³C-Methacetin Breath Tests in BMS: NCT03486899, NCT03486912 Referenced TrialsCompletedNCT03611101Results posted
• Hepatic Mitochondrial Function in YouthCompletedNCT03587727Results posted
• Spironolactone Therapy In Young Women With NASHCompletedNCT03576755Phase 1/2Results posted
• A Study to Evaluate Seladelpar in Subjects With Nonalcoholic Steatohepatitis (NASH)TerminatedNCT03551522Phase 2Results posted
• Mild Hypothermia and Acute Kidney Injury in Liver TransplantationTerminatedNCT03534141Not applicableResults posted
• Study of Safety, Tolerability, and Efficacy of a Combination Treatment of LJN452 and CVC in Adult Patients With NASH and Liver FibrosisCompletedNCT03517540Phase 2Results posted
• 2-Week Study In People With Nonalcoholic Fatty Liver DiseaseCompletedNCT03513588Phase 1Results posted
• Study of Gemcabene in Adults With FPLDCompletedNCT03508687Phase 1/2Results posted
• A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Liver CirrhosisCompletedNCT03486912Phase 2Results posted
• A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Stage 3 Liver FibrosisCompletedNCT03486899Phase 2Results posted
• Losartan for the Treatment of Pediatric NAFLDTerminatedNCT03467217Phase 2Results posted
• Lanifibranor in Patients With Type 2 Diabetes & Nonalcoholic Fatty Liver DiseaseCompletedNCT03459079Phase 2Results posted
• Study to Evaluate the Safety and Efficacy of Selonsertib, Firsocostat, Cilofexor, and Combinations in Participants With Bridging Fibrosis or Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)CompletedNCT03449446Phase 2Results posted
• Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic SteatohepatitisCompletedNCT03439254Phase 3Results posted
• Companion Protocol for Methacetin Breath Test (MBT) in Conatus Protocol IDN-6556-14CompletedNCT03439189Results posted
• Gemcabene for the Treatment of Pediatric NAFLDTerminatedNCT03436420Phase 2Results posted
• A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Non-Alcoholic SteatohepatitisCompletedNCT03421431Phase 2Results posted
• A Sub-study of BMS-986036 in Subjects With Non-Alcoholic Steatohepatitis (NASH)CompletedNCT03400163Phase 2Results posted
• Growth Hormone Releasing Hormone Analog to Improve Nonalcoholic Fatty Liver Disease and Associated Cardiovascular RiskCompletedNCT03375788Phase 2Results posted
• Effect on Liver Fat and Metabolic Parameters When Switching a Protease Inhibitor or Efavirenz to RaltegravirCompletedNCT03374358Phase 4Results posted
• Study of ISIS 703802 in Participants With Hypertriglyceridemia, Type 2 Diabetes Mellitus, and Nonalcoholic Fatty Liver DiseaseCompletedNCT03371355Phase 2Results posted
• Effects of Dietary Fructose on Gut Microbiota and Fecal Metabolites in Obese Men and Postmenopausal Women: A Pilot StudyCompletedNCT03339245Not applicableResults posted
• Safety, Tolerability, and Pharmacodynamics of IONIS-DGAT2Rx in Adult Patients With Type 2 DiabetesCompletedNCT03334214Phase 2Results posted
• A Study of Experimental Medication BMS-986251, Taken by Mouth, in Healthy Participants and Patients With Average to Very Serious PsoriasisTerminatedNCT03329885Phase 1/2Results posted
• The HepQuant SHUNT Test for Monitoring Liver Disease and Treatment Effects by Measuring Liver Function and PhysiologyTerminatedNCT03294941Phase 2Results posted
• Biomarkers of Liver Pathology in Patients With Presumed Non-Alcoholic Steatohepatitis Following Bariatric SurgeryCompletedNCT03294850Not applicableResults posted
• 6-week Safety and PD Study in Adults With NAFLDCompletedNCT03256526Phase 2Results posted
• Phase 2a, Dose-ranging Study With PF-05221304 in Nonalcoholic Fatty Liver Disease (NAFLD)CompletedNCT03248882Phase 2Results posted
• Effect of LIK066 on Reduction of Fatty Content in Livers of Obese PatientsCompletedNCT03205150Phase 2Results posted
• Different Doses of BI 1467335 Compared to Placebo in Patients With Clinical Evidence of NASHCompletedNCT03166735Phase 2Results posted
• Pradaxa Tablet Proton Pump Inhibitor (PPI) Bioavailability (BA) Study in JapanCompletedNCT03143166Phase 1Results posted
• Saroglitazar Magnesium in Patients With Nonalcoholic Fatty Liver Disease and/or Nonalcoholic SteatohepatitisCompletedNCT03061721Phase 2Results posted
• Rollover Study of Cenicriviroc for the Treatment of Liver Fibrosis in Participants With Nonalcoholic SteatohepatitisTerminatedNCT03059446Phase 2Results posted
• Safety and Efficacy of Selonsertib in Adults With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)TerminatedNCT03053063Phase 3Results posted
• Safety and Efficacy of Selonsertib in Adults With Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) FibrosisTerminatedNCT03053050Phase 3Results posted
• Anti-LPS Antibody Treatment for Pediatric NAFLDCompletedNCT03042767Phase 2Results posted
• Post-Prandial Liver Glucose Metabolism in PCOSCompletedNCT03041129Results posted
• AURORA: A Study for the Efficacy and Safety of Cenicriviroc (CVC) for the Treatment of Liver Fibrosis in Adults With Nonalcoholic Steatohepatitis (NASH)TerminatedNCT03028740Phase 3Results posted
• Palliative Care for Non-Malignant Diseases (COMPASS Trial)TerminatedNCT03022630Not applicableResults posted
• Phase 2b Study in NASH to Assess IVA337CompletedNCT03008070Phase 2Results posted
• A Prospective Study of HBV Immunity and HBV Vaccination in Patients With NAFLD in CanadaCompletedNCT02985450Results posted
• Investigation of Efficacy and Safety of Three Dose Levels of Subcutaneous Semaglutide Once Daily Versus Placebo in Subjects With Non-alcoholic Steatohepatitis.CompletedNCT02970942Phase 2Results posted
• Emricasan, an Oral Caspase Inhibitor, in Subjects With NASH Cirrhosis and Severe Portal HypertensionCompletedNCT02960204Phase 2Results posted
• Safety And Efficacy Study Of Orally Administered Epeleuton In Patients With NAFLDCompletedNCT02941549Phase 2Results posted
• Safety, Tolerability, Pharmacokinetics and Efficacy of LMB763 in Patients With NASHTerminatedNCT02913105Phase 2Results posted
• Study to Evaluate the Pharmacokinetics of Firsocostat or Fenofibrate in Adults With Normal and Impaired Hepatic FunctionCompletedNCT02891408Phase 1Results posted

← Fatty Liver overview